de novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases.

[1]  D. Rosenthal,et al.  Chronic myelomonocytic leukemia. , 1990, Leukemia.

[2]  A. Gratwohl,et al.  Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) , 1990, British journal of haematology.

[3]  S. Nimer,et al.  Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Audebert,et al.  Refractory anemia with excess of blasts in transformation. Clinical, hematologic, and cytogenetic findings in nine patients. , 1989, Cancer genetics and cytogenetics.

[5]  A. Farrow,et al.  Myelodysplasia, chemical exposure, and other environmental factors. , 1989, Leukemia.

[6]  P. Fenaux,et al.  Aggressive chemotherapy in adult primary myelodysplastic syndromes. A report on 29 cases. , 1988, Blut.

[7]  R. Beuscart,et al.  Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Czepulkowski,et al.  Childhood monosomy 7 revisited , 1988, British journal of haematology.

[9]  D. Oscier.  5 Myelodysplastic syndromes , 1987 .

[10]  T. Economopoulos,et al.  Myelodysplastic syndromes: Analysis of 131 cases according to the FAB classification , 1987, European journal of haematology.

[11]  R. Verwilghen,et al.  The myelodysplastic syndromes. , 1987, Blood reviews.

[12]  J. Hermans,et al.  Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases , 1987, British journal of haematology.

[13]  R. Wegelius.  Preleukaemic states in children. , 2009, Scandinavian journal of haematology. Supplementum.

[14]  G. Tricot,et al.  Prognostic factors in the myelodysplastic syndromes: a review. , 2009, Scandinavian journal of haematology. Supplementum.

[15]  E. Polli,et al.  Inhibition of proliferation of human leukaemic cell populations by deferoxamine. , 2009, Scandinavian journal of haematology.

[16]  Levin Eg,et al.  Secondary myelodysplastic syndromes and leukaemias. , 1986 .

[17]  F. Mitelman,et al.  Chromosome abnormalities in the myelodysplastic syndromes. , 1986, Clinics in haematology.

[18]  G. Tricot,et al.  The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes , 1986, British journal of haematology.

[19]  M. Oken,et al.  Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. , 1986, Blood.

[20]  D. Machin,et al.  Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.

[21]  A. Williams,et al.  The myelodysplastic syndrome: analysis of laboratory characteristics in relation to the FAB classification , 1985, British journal of haematology.

[22]  D. Rosenthal,et al.  Refractory dysmyelopoietic anemia and acute leukemia. , 1984, Blood.

[23]  B. Coiffier,et al.  Dysmyelopoietic syndromes a search for prognostic factors in 193 patients , 2006, Cancer.

[24]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[25]  C Hogstedt,et al.  Leukemia in workers exposed to ethylene oxide. , 1979, JAMA.

[26]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .